Hybrigenics' revenues dip 5% but inecalcitol still promising
This article was originally published in Scrip
Executive Summary
A sharp fall in the contribution from its pharma division pulled overall revenues at Hybrigenics, the French biopharmaceutical company focused on novel targets and therapies for cancer, down by 5% to €4.5 million in 2010.